Meta Analysis of Therapeutic Efficacy of Sodium Tanshinone ⅡA Sulfonate Injection in Treatment of Diabetic Kidney Disease

OBJECTIVE To systematically evaluate the therapeutic efficacy of sodium tanshinoneⅡA sulfonate injection in the treatment of diabetic kidney disease(DKD), and provide a certain reference for clinical rational application. METHODS Retrieved from PubMed, CNKI, VIP, Wanfang and CBM database, the trials about sodium tanshinoneⅡA sulfonate injection in treatment of DKD were collected. And studies were screened according to inclusion and excluding criteria. Meta-analysis of included studies was performed using RevMan 5.3 software after quality evaluation and valid data extraction. RESULTS A total of 15 randomized controlled trials(RCTs) were included, involving 1 202 patients. Meta-analysis showed that experimental group and control group had statistically difference in clinical efficacyRR=1.44, 95%CI(1.12, 1.84), P=0.005, urinary albumin excretion rateMD=-20.18, 95%CI(-33.76, -6.59), P=0.004, 24 h urinary protein excretionMD=-0.35, 95%CI(-0.45, -0.26), P<0.000 01, total cholesterolMD=-0.69, 95%CI(-1.00, -0.37), P<0.000 1, triacylglycerolMD=-0.58, 95%CI(-0.89, -0.26), P=0.000 3, serum creatinineMD=-15.44, 95%CI(-24.71, -6.17), P=0.001. But there was no statistically difference in fasting plasma glucoseMD=-0.22, 95%CI(-0.51, 0.06), P=0.12. CONCLUSION Evidence show that sodium tanshinone Ⅱ A sulfonate injection has no significant effect on fasting blood glucose in DKD patient, but it can significantly reduce the urine protein, serum creatinine and blood lipid level.However, due to the lack of clinical RCTs designed for all stages of DKD at present, the inclusion criteria of this study is relatively broad, and the results are lack of pertinence, with obvious inter-group heterogeneity. So it still need more relevant high-quality RCTs with large sample for further study of the clinical effect for sodium tanshinoneⅡA sulfonate injection in adjuvant treatment of DKD.